Will this patient respond to fosfamycin (a broad-spectrum antibiotic) given the bacteria's susceptibility pattern?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fosfomycin Response for the Patient Based on Susceptibility Testing

Based on the provided susceptibility data, this patient would likely respond well to fosfomycin for a urinary tract infection caused by the tested organism. 1, 2

Susceptibility Analysis

  • The susceptibility data shows the organism is sensitive to multiple antibiotics including aminoglycosides, cephalosporins, fluoroquinolones, and carbapenems, suggesting it is likely an Enterobacterales species 3
  • While fosfomycin susceptibility is not explicitly listed in the provided data, Enterobacterales (particularly E. coli and Klebsiella) generally show good susceptibility to fosfomycin 4, 5
  • The organism shows resistance to ampicillin but sensitivity to ampicillin-sulbactam (intermediate in one test), suggesting a beta-lactamase producer that may still be susceptible to fosfomycin 3

Clinical Efficacy for UTIs

  • Fosfomycin is highly effective as a first-line treatment for uncomplicated urinary tract infections, with a single 3-gram oral dose providing therapeutic urinary concentrations for 24-48 hours 1, 2
  • Following oral administration, fosfomycin achieves mean urinary concentrations of 706 μg/mL within 2-4 hours, well above the MIC breakpoint for susceptible organisms (≤64 μg/mL) 2, 6
  • Therapeutic urinary concentrations of fosfomycin (>100 μg/mL) are maintained for approximately 26 hours after a single dose 2

Important Considerations

  • Fosfomycin is FDA-approved only for uncomplicated lower UTIs (cystitis) and should not be used for pyelonephritis or complicated UTIs as monotherapy 5, 1
  • For complicated UTIs or pyelonephritis, alternative agents from the susceptibility panel (such as fluoroquinolones or cephalosporins) would be more appropriate 3, 5
  • The organism shows variable susceptibility to nitrofurantoin (resistant in one test, sensitive in another), making fosfomycin potentially more reliable 6

Treatment Recommendations

  • For uncomplicated lower UTI: Fosfomycin 3g oral powder dissolved in water as a single dose 1, 2
  • For complicated UTI or pyelonephritis: Consider alternatives from the susceptibility panel such as ceftriaxone, ciprofloxacin, or levofloxacin based on the provided sensitivity data 3, 5
  • If using fosfomycin for a multidrug-resistant organism, be aware that clinical data specifically for non-E. coli Enterobacterales is more limited 4, 7

Monitoring and Follow-up

  • If symptoms do not resolve within 2-3 days or recur within 2 weeks after fosfomycin treatment, perform follow-up urine culture and consider alternative antibiotics based on the susceptibility panel 1
  • Common adverse effects to monitor include diarrhea, nausea, and vomiting 1, 2

Antibiotic Stewardship Considerations

  • Fosfomycin has minimal propensity for collateral damage to intestinal flora compared to fluoroquinolones and broad-spectrum cephalosporins 4, 1
  • Despite increased clinical use, fosfomycin has maintained good activity against Enterobacterales, making it a valuable option for uncomplicated UTIs 8, 6

References

Guideline

Fosfomycin Treatment for Uncomplicated Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fosfomycin for Klebsiella pneumoniae UTI

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Fosfomycin for Uncomplicated Lower Urinary Tract Infections Caused by ESBL-Producing Klebsiella

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.

Antimicrobial agents and chemotherapy, 2015

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.